S&P 500   3,383.49 (+1.49%)
DOW   27,959.99 (+0.99%)
QQQ   272.58 (+2.79%)
AAPL   452.83 (+3.50%)
MSFT   210.04 (+3.27%)
FB   261.42 (+2.07%)
GOOGL   1,509.58 (+1.96%)
AMZN   3,166.51 (+2.79%)
NVDA   456.92 (+5.28%)
CGC   17.40 (+2.65%)
BABA   255.54 (+2.87%)
TSLA   1,552.82 (+12.98%)
GE   6.63 (-1.49%)
MU   48.58 (+1.72%)
AMD   82.44 (+7.23%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.86 (-1.60%)
GILD   68.89 (+1.16%)
NFLX   480.44 (+2.89%)
DIS   131.35 (+0.66%)
BAC   26.62 (-1.11%)
BA   173.96 (-3.43%)
S&P 500   3,383.49 (+1.49%)
DOW   27,959.99 (+0.99%)
QQQ   272.58 (+2.79%)
AAPL   452.83 (+3.50%)
MSFT   210.04 (+3.27%)
FB   261.42 (+2.07%)
GOOGL   1,509.58 (+1.96%)
AMZN   3,166.51 (+2.79%)
NVDA   456.92 (+5.28%)
CGC   17.40 (+2.65%)
BABA   255.54 (+2.87%)
TSLA   1,552.82 (+12.98%)
GE   6.63 (-1.49%)
MU   48.58 (+1.72%)
AMD   82.44 (+7.23%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.86 (-1.60%)
GILD   68.89 (+1.16%)
NFLX   480.44 (+2.89%)
DIS   131.35 (+0.66%)
BAC   26.62 (-1.11%)
BA   173.96 (-3.43%)
S&P 500   3,383.49 (+1.49%)
DOW   27,959.99 (+0.99%)
QQQ   272.58 (+2.79%)
AAPL   452.83 (+3.50%)
MSFT   210.04 (+3.27%)
FB   261.42 (+2.07%)
GOOGL   1,509.58 (+1.96%)
AMZN   3,166.51 (+2.79%)
NVDA   456.92 (+5.28%)
CGC   17.40 (+2.65%)
BABA   255.54 (+2.87%)
TSLA   1,552.82 (+12.98%)
GE   6.63 (-1.49%)
MU   48.58 (+1.72%)
AMD   82.44 (+7.23%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.86 (-1.60%)
GILD   68.89 (+1.16%)
NFLX   480.44 (+2.89%)
DIS   131.35 (+0.66%)
BAC   26.62 (-1.11%)
BA   173.96 (-3.43%)
S&P 500   3,383.49 (+1.49%)
DOW   27,959.99 (+0.99%)
QQQ   272.58 (+2.79%)
AAPL   452.83 (+3.50%)
MSFT   210.04 (+3.27%)
FB   261.42 (+2.07%)
GOOGL   1,509.58 (+1.96%)
AMZN   3,166.51 (+2.79%)
NVDA   456.92 (+5.28%)
CGC   17.40 (+2.65%)
BABA   255.54 (+2.87%)
TSLA   1,552.82 (+12.98%)
GE   6.63 (-1.49%)
MU   48.58 (+1.72%)
AMD   82.44 (+7.23%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.86 (-1.60%)
GILD   68.89 (+1.16%)
NFLX   480.44 (+2.89%)
DIS   131.35 (+0.66%)
BAC   26.62 (-1.11%)
BA   173.96 (-3.43%)
Log in

NYSE:ABBVAbbVie Stock Price, Forecast & News

$95.27
+2.60 (+2.81 %)
(As of 08/12/2020 02:37 PM ET)
Add
Compare
Today's Range
$93.00
Now: $95.27
$95.34
50-Day Range
$92.38
MA: $97.07
$100.83
52-Week Range
$62.55
Now: $95.27
$101.28
Volume281,840 shs
Average Volume6.54 million shs
Market Capitalization$168.14 billion
P/E Ratio20.27
Dividend Yield5.11%
Beta0.83
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; and Calico Life Sciences LLC. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More
AbbVie logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 3.3Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.38 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP00287Y10
Phone847-932-7900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$33.27 billion
Cash Flow$10.66 per share
Book Value$8.35 per share

Profitability

Net Income$7.88 billion

Miscellaneous

Employees30,000
Outstanding Shares1,764,830,000
Market Cap$168.14 billion
Next Earnings Date11/6/2020 (Estimated)
OptionableOptionable
$95.27
+2.60 (+2.81 %)
(As of 08/12/2020 02:37 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AbbVie (NYSE:ABBV) Frequently Asked Questions

How has AbbVie's stock been impacted by COVID-19 (Coronavirus)?

AbbVie's stock was trading at $84.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ABBV stock has increased by 11.9% and is now trading at $94.91.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of AbbVie?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for AbbVie
.

When is AbbVie's next earnings date?

AbbVie is scheduled to release its next quarterly earnings announcement on Friday, November 6th 2020.
View our earnings forecast for AbbVie
.

How were AbbVie's earnings last quarter?

AbbVie Inc (NYSE:ABBV) released its quarterly earnings results on Friday, July, 31st. The company reported $2.34 EPS for the quarter, topping analysts' consensus estimates of $2.20 by $0.14. The company had revenue of $10.43 billion for the quarter, compared to analysts' expectations of $10.14 billion. AbbVie had a negative return on equity of 628.57% and a net margin of 19.20%. The firm's revenue for the quarter was up 26.3% compared to the same quarter last year. During the same quarter last year, the firm posted $2.26 earnings per share.
View AbbVie's earnings history
.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Wednesday, June 17th. Shareholders of record on Wednesday, July 15th will be given a dividend of $1.18 per share on Friday, August 14th. This represents a $4.72 annualized dividend and a yield of 4.97%. The ex-dividend date is Tuesday, July 14th.
View AbbVie's dividend history
.

How will AbbVie's stock buyback program work?

AbbVie announced that its Board of Directors has authorized a stock repurchase plan on Thursday, December 13th 2018, which permits the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 3.8% of its stock through open market purchases. Stock buyback plans are usually an indication that the company's board of directors believes its stock is undervalued.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie issued an update on its FY20 earnings guidance on Friday, July, 31st. The company provided EPS guidance of $10.35-10.45 for the period, compared to the Thomson Reuters consensus EPS estimate of $10.51.

What price target have analysts set for ABBV?

17 brokers have issued 12 month target prices for AbbVie's stock. Their forecasts range from $90.00 to $127.00. On average, they anticipate AbbVie's stock price to reach $107.00 in the next twelve months. This suggests a possible upside of 12.7% from the stock's current price.
View analysts' price targets for AbbVie
.

Has AbbVie been receiving favorable news coverage?

Headlines about ABBV stock have trended negative on Wednesday, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AbbVie earned a news sentiment score of -2.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future.
View the latest news about AbbVie
.

Who are some of AbbVie's key competitors?

What other stocks do shareholders of AbbVie own?

Who are AbbVie's key executives?

AbbVie's management team includes the following people:
  • Mr. Richard A. Gonzalez, Chairman & CEO (Age 65)
  • Dr. Michael E. Severino, Vice Chairman & Pres (Age 53)
  • Mr. Robert A. Michael, Sr. VP & CFO (Age 49)
  • Mr. William J. Chase, Exec. VP of Fin. & Admin. (Age 51)
  • Ms. Laura J. Schumacher, Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec. (Age 56)

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a variety of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.55%), Swiss National Bank (0.47%), PNC Financial Services Group Inc. (0.30%), California Public Employees Retirement System (0.23%), New York State Common Retirement Fund (0.23%) and LSV Asset Management (0.26%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Roxanne S Austin, Timothy J Richmond and William J Chase.
View institutional ownership trends for AbbVie
.

Which institutional investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including LSV Asset Management, Toronto Dominion Bank, Russell Investments Group Ltd., Bank of Nova Scotia, Victory Capital Management Inc., ProShare Advisors LLC, Hamlin Capital Management LLC, and Great Lakes Advisors LLC. Company insiders that have sold AbbVie company stock in the last year include Carlos Alban, Jeffrey Ryan Stewart, and Timothy J Richmond.
View insider buying and selling activity for AbbVie
.

Which institutional investors are buying AbbVie stock?

ABBV stock was acquired by a variety of institutional investors in the last quarter, including Healthcare of Ontario Pension Plan Trust Fund, Sumitomo Mitsui Trust Holdings Inc., Swiss National Bank, Newport Trust Co, First Trust Advisors LP, California Public Employees Retirement System, Los Angeles Capital Management & Equity Research Inc., and New York State Common Retirement Fund. Company insiders that have bought AbbVie stock in the last two years include Brian L Durkin, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin, and William J Chase.
View insider buying and selling activity for AbbVie
.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $94.91.

How big of a company is AbbVie?

AbbVie has a market capitalization of $167.50 billion and generates $33.27 billion in revenue each year. The company earns $7.88 billion in net income (profit) each year or $8.94 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.

What is AbbVie's official website?

The official website for AbbVie is www.abbvie.com.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.